No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Earnings misses, bad planning, and product-line execution problems are all hitting the retailer, but it's the macro woes that will also hurt its competitors.
After a 2018 high, marijuana stocks are gaining popularity again, but which ones are producing the most green for investors? Here are the charts.
What new management means for Mylan shareholders moving forward.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
A big jump in the market cap of Google's parent is in store thanks to an impressive second-quarter report.
Volatility reigns once again at the electric carmaker, which is seeing JB Straubel depart as chief technology officer.
Big-cap names have been driving the market, but some small-caps could make noise, too.